Sun Pharmaceutical Industries reported a 5% YoY increase in consolidated profit of Rs 2,166 crore for the quarter ended December 31, 2022, compared to Rs 2,059 crore the previous year on January 31. It was 4% lower than the Rs 2,262 crore recorded in the previous quarter.
The Indian pharma major’s consolidated revenue from operations increased 14 percent to Rs 11,241 crore, up from Rs 9,863 crore in the December 2021 quarter. In Q2FY23, revenue was Rs 10,952 crore.
The board of directors of the firm declared an interim dividend of Rs 7.50 for the fiscal year ending March 31, 2023.
Sun Pharma shares were trading 2% down on the NSE at Rs 1032.30 a share at 2.27 p.m. on Tuesday.
Earnings before interest, depreciation, taxation, and amortisation (EBITDA) were Rs 3,004 crore, up 15% from Rs 2,606 crore recorded previous year. EBITDA margin increased by 30 basis points year on year to 26.7 percent, up from 26.4 percent the previous year.